GRAL
GRAIL, LLCNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$2.39B
P/E Ratio
—
EPS
$-11.44
Beta
—
52W High
$118.84
52W Low
$29.95
50-Day MA
$50.41
200-Day MA
$66.88
Dividend Yield
—
Profit Margin
-277.50%
Forward P/E
—
PEG Ratio
—
About GRAIL, LLC
GRAIL, LLC is a leading biotechnology innovator specializing in groundbreaking blood tests for early cancer detection, leveraging its proprietary genomic technologies to transform the multi-cancer early detection (MCED) landscape. By providing individuals with crucial insights for proactive health management, GRAIL is committed to advancing precision medicine and significantly improving patient outcomes. The company's pioneering efforts aim to fill critical gaps in existing cancer screening and diagnostics, solidifying its position as a vital entity in the evolving oncology sector.
Fundamentals
| Revenue (TTM) | $147.17M |
| Gross Profit (TTM) | $71.32M |
| EBITDA | $-377.85M |
| Operating Margin | -285.40% |
| Return on Equity | -16.10% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $4.00 |
| Book Value | $63.92 |
| Price-to-Book | 0.90 |
| Price-to-Sales (TTM) | 16.23 |
| EV/Revenue | 9.99 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 14.00% |
| Shares Outstanding | $42.92M |
| Float | $34.65M |
| % Insiders | 4.72% |
| % Institutions | 71.73% |
Analyst Ratings
Consensus ($67.71 target)
4
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/5/2026